SGMT Sagimet Biosciences

Watchlist

3.715
+0.105+2.91%

Close Feb 28 16:00 ET

3.700
-0.015-0.40%

Post 20:01 ET

119.61MMarket Cap-3.19P/E (TTM)

About Sagimet Biosciences Company

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Company Profile

SymbolSGMT

Company NameSagimet Biosciences

Listing DateJul 14, 2023

Issue Price16.00

Founded2006

CEOMr. David Happel

MarketNASDAQ

Employees10

Fiscal Year Ends12-31

Address155 Bovet Road,Suite 303

CitySan Mateo

ProvinceCalifornia

CountryUnited States of America

Zip Code94402

Phone1-650-561-8600

Websitehttp://www.sagimet.com

Company Executives

Name
Position
Salary

David Happel
President, Chief Executive Officer and Director
2.69M

Thierry Chauche
Chief Financial Officer and Principal Accounting Officer
--

Elizabeth Rozek
General Counsel and Chief Compliance Officer
--

Dr. Eduardo Bruno Martins, D.Phil.,M.D.
Chief Medical Officer
1.51M

George Kemble, PhD
Executive Chairman of the Board
930.22K

Dr. Anne M. Phillips, M.D.
Independent Director
--

Elizabeth Grammer
Independent Director
43.00K

Dr. Beth C. Seidenberg,M.D.
Independent Director
14.38K

Jennifer Ann Jarrett
Independent Director
--

Dr. Merdad V. Parsey, M.D.,PhD
Independent Director
41.50K

SGMT Sagimet Biosciences

About Sagimet Biosciences Company

Company Profile

Company Executives

Trending Stocks